NTT東日本関東病院は、東京都品川区で東日本電信電話が運営する企業立病院である。1999年、それまでの関東逓信病院から改称した。

During the past decade, NTT Medical Center Tokyo conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 21 clinical trials were completed, i.e. on average, 42% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 18 clinical trials were completed. i.e. 72% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NTT Medical Center Tokyo" #1 sponsor was "Celgene" with 8 trials, followed by "Amgen" with 6 trials sponsored, "Pfizer" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Hoffmann-La Roche" with 4 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NTT Medical Center Tokyo" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "NTT Medical Center Tokyo" are "Psoriasis" (7 trials), "Acute Myeloid Leukemia" (5 trials), "Atopic Dermatitis" (3 trials), "Myelodysplastic Syndrome" (3 trials) and "Myelodysplastic Syndromes" (3 trials). Many other conditions were trialed in "NTT Medical Center Tokyo" in a lesser frequency.

Most popular intervention types in "NTT Medical Center Tokyo" are "Drug" (52 trials), "Other" (4 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Apremilast" (4 trials), "Azacitidine" (3 trials), "BMS-986165" (3 trials) and "Crovalimab" (3 trials). Other intervention names were less common.

The vast majority of trials in "NTT Medical Center Tokyo" are 56 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "NTT Medical Center Tokyo". undefined are not yet recruiting, 10 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in NTT Medical Center Tokyo, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in NTT Medical Center Tokyo, 10 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".